Global Nucleic Acid Therapeutics Market 2020-2024 with Focus on Oligonucleotide - ResearchAndMarkets.com

·5 min read

The "Global Nucleic Acid Therapeutics Market (with Focus on Oligonucleotide): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

The global nucleic acid therapeutics market is expected to record a value of US$7.23 billion in 2024, increasing at a CAGR of 33.3%, for the duration spanning 2020-2024.

The factors such as rising incidences of new cancer cases, rising penetration of gene therapy, increasing pharmaceutical R&D spending, rise in prevalence of diabetes, upsurge in healthcare expenditures and rapid advances in nucleic acid technologies for diagnostics would drive the growth of the market.

However, the market growth would be challenged by the challenge of delivering nucleic acid therapeutics, development hurdles for RNAi therapeutics and legal regulations. A few notable trends may include, accelerating growth rates of infectious diseases, progress in pharmaceutical and biotech merger & acquisition, growth in government spending on healthcare and development of nucleic acid therapeutics.

The global nucleic acid therapeutics market holds a very lucrative scope as such class of compounds have emerged in recent years to yield extremely promising candidates for drug therapy to a wide range of diseases. Based on application, nucleic acid therapeutics are widely used for the treatment of mono-genetic disorders and multi-genetic disorders. The high prevalence of various monogenetic diseases is leading to the rising application of various nucleic acid therapeutics, which is likely to help in its market growth in future.

The fastest regional market was the Americas due to the presence of major players and the well-established R&D infrastructure, which helped in the development of various nucleic acid therapeutics. Further, owing to the sudden outbreak of COVID-19, scientists are evaluating various biomolecules and synthetic inhibitors against COVID-19; where the nucleic acid-based molecules may be considered as potential drug candidates, which is posing as an opportunity for the market growth of the nucleic acid therapeutics globally.

Scope of the report:

  • The report provides a comprehensive analysis of the global nucleic acid therapeutics market.

  • The major regional markets (Americas, Europe, Asia-Pacific and Middle East & Africa) have been analyzed.

  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

  • The competitive landscape of the market, along with the company profiles of leading players (Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Benitec Biopharma, WAVE Life Sciences, Vir Biotechnology and Protagonist Therapeutics) are also presented in detail.

Key Target Audience:

  • Nucleic Acid and Oligonucleotide Therapeutics Manufacturers

  • Pharmaceuticals and Biopharmaceutical Firms

  • End Users (Hospitals and Research Institutes)

  • Investment Banks

  • Healthcare and Medical Consultants.

  • Government Bodies & Regulating Authorities

Key Topics Covered:

1. Overview

1.1 Introduction

1.2 Difference Between DNA and RNA

1.3 Nucleoside, Nucleotide & Nucleic Acid

1.4 Oligonucleotides

1.5 Comparison of ASO and siRNA Mechanisms

1.6 Nucleic Acid as Therapeutics

1.7 Categories of Nucleic Acid Therapeutics

1.8 Nucleic Acid Therapeutics in Gene Therapy

2. Impact of COVID-19

2.1 Rise in COVID-19 Testing

2.2 Growth in COVID-19 R&D Funding

2.3 Nucleic Acid Vaccines for COVID-19

2.4 Oligonucleotides and COVID-19 Pandemic

3. Global Nucleic Acid Therapeutics Market Analysis

3.1 Global Nucleic Acid Therapeutics Market by Value

3.2 Global Nucleic Acid Therapeutics Market Forecast by Value

3.3 Global Nucleic Acid Therapeutics Market Value by Application

3.3.1 Global Mono Genetic Nucleic Acid Therapeutics Market by Value

3.3.2 Global Mono Genetic Nucleic Acid Therapeutics Market Forecast by Value

3.3.3 Global Multi Genetic Nucleic Acid Therapeutics Market by Value

3.3.4 Global Multi Genetic Nucleic Acid Therapeutics Market Forecast by Value

4. Global Oligonucleotide Therapeutics Market Analysis

4.1 Global Oligonucleotide Therapeutics Market by Value

4.2 Global Oligonucleotide Therapeutics Market Forecast by Value

4.3 Global Oligonucleotide Therapeutics Market Value by Drugs Class

4.3.1 Global ASO (Antisense Oligonucleotide) Therapeutics Market by Value

4.3.2 Global ASO (Antisense Oligonucleotide) Therapeutics Market Forecast by Value

4.3.3 Global SiRNA (Small interfering RNA) Therapeutics Market Forecast by Value

4.4 Global Oligonucleotide Therapeutics Market Value by Regions

5. Regional Oligonucleotide Therapeutics Market Analysis

5.1 Americas

5.1.1 Americas Oligonucleotide Therapeutics Market Forecast by Value

5.2 Europe

5.3 Asia Pacific

5.4 Middle East & Africa

6. Market Dynamics

6.1 Growth Drivers

6.1.1 Rising Incidences of New Cancer Cases

6.1.2 Rising Penetration of Gene Therapy

6.1.3 Increasing Pharmaceutical R&D Spending

6.1.4 Rise in Prevalence of Diabetes

6.1.5 Upsurge in Healthcare Expenditures

6.1.6 Rapid Advances in Nucleic Acid Technologies for Diagnostics

6.2 Key Trends and Developments

6.2.1 Accelerating Growth Rates of Infectious Diseases

6.2.2 Progress in Pharmaceutical and Biotech Merger & Acquisition

6.2.3 Growth in Government Spending on Healthcare

6.2.4 Development of Nucleic Acid Therapeutics

6.3 Challenges

6.3.1 Challenge of Delivering Nucleic Acid Therapeutics

6.3.2 Development Hurdles for RNAi Therapeutics

6.3.3 Legal Regulations

7. Competitive Landscape

7.1 Global Market

7.1.1 Key Players - Revenue Comparison

7.1.2 Key Players - R&D Expenditure Comparison

7.1.3 Key Players - Market Capitalization Comparison

7.1.4 Key Players - Nucleic Acid Drug Development and Patent Portfolio

8. Company Profiles

8.1 Business Overview

8.2 Financial Overview

8.3 Business Strategies

  • Alnylam Pharmaceuticals

  • Arrowhead Pharmaceuticals

  • Benitec Biopharma

  • Protagonist Therapeutics

  • Vir Biotechnology

  • WAVE Life Sciences

For more information about this report visit https://www.researchandmarkets.com/r/trnop2

View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005185/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900